Juventas begins enrollment of heart failure drug study
Juventas Therapeutics has begun to evaluate the safety and efficacy of treatments for patients with Class III heart failure (HF) by conducting a phase I clinical trial to assess the use of JVS-100, an encoder of Stromal-cell Derived Factor 1 (SDF-1).

JVS-100 has been shown in pre-clinical models—HF pig models—to increase cardiac function, repair tissue and increase blood vessel formation in damaged organs. The open-label, dose-escalation trial will enroll 16 patients and be led by principal investigator Douglas Losordo, MD, of the Feinberg Cardiovascular Research Institute at Northwestern University, according to the biotechnology company.

SDF-1 accelerates the healing process by “recruiting endothelial progenitor cells to damaged organs to induce neovascularization and angiogenesis,” according to Juventas.

Cleveland-based Juventas said that JVS-100 has the potential to produce similar benefits to regenerative medicine without the need to distribute stem cells in patients.

"Humans have evolved in such a way that our natural SDF-1 expression is too short-lived for us to see any benefit; however, by delivering JVS-100, we prolong SDF-1 expression or re-introduce it at a time remote from injury for a period of time sufficient to promote significant tissue repair," noted Marc Penn, MD, PhD, chief scientific officer for Juventas.

Activating the SDF-1 repair pathway and treating patients with JVS-100 can be beneficial in repairing tissue in any of the main organ systems including the heart, brain, kidney, dermis, vasculature and nervous system, according to the company.

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup